



**Press release**  
April 2, 2020  
Gothenburg

## Conference call on Interim Report

**Invitation to attend XVIVO Perfusion's conference call regarding the presentation of the interim report January - March 2020. The presentation will be held in English.**

Time: Thursday, April 9, 2020 at 11.30 a.m. CET

Information regarding the conference can be found under the following link:  
<https://event.on24.com/wcc/r/2239698/BC3013723908BBA313809D53E82CDF15>

Phone numbers to the conference:  
Sweden dial in number: +46 856 642 651  
USA dial in number: +1 631 913 1422  
International (UK) dial in number: +44 (0)3333 000 804  
Conference name: XVIVO Perfusion, Conference ID: 52504358#

Participants from XVIVO Perfusion:  
Magnus Nilsson, CEO  
Christoffer Rosenblad, CFO

The press release for XVIVO Perfusion's interim report January – March 2020 will be released on April 9, 2020 at 7:30 a.m. CET.

Before the conference call, slides will be available at the company web page, [www.xvivoperfusion.com/corporate/](http://www.xvivoperfusion.com/corporate/).

April 2, 2020  
Gothenburg  
XVIVO Perfusion AB (publ)

For further information, please contact  
Christoffer Rosenblad, CFO, +46 735 192159, [christoffer.rosenblad@xivoperfusion.com](mailto:christoffer.rosenblad@xivoperfusion.com)  
Magnus Nilsson, CEO, +46 31-788 21 50, [magnus.nilsson@xivoperfusion.com](mailto:magnus.nilsson@xivoperfusion.com)

---

XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation. The company is headquartered in Gothenburg, Sweden, and has one office in Lund, Sweden and one office in the USA. The XVIVO share is listed on Nasdaq Stockholm and has the ticker symbol XVIVO. More information can be found on the website [www.xvivoperfusion.com](http://www.xvivoperfusion.com).

---

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.  
Tel: +46 31 788 21 50. Fax: +46 31 788 21 69.  
E-mail: [info@xivoperfusion.com](mailto:info@xivoperfusion.com). Website: [www.xvivoperfusion.com](http://www.xvivoperfusion.com)

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.